Search

Search Constraints

You searched for: Author/Creator Kato, Ryoji

Search Results

1. [fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification. Issue 12 (24th May 2019)

3. Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer. (January 2022)

4. Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb‐202 in gastric cancer. Issue 6 (1st June 2021)

5. Gamma‐aminobutyric acid transaminase genetic polymorphism is a candidate locus for responsiveness to opioid analgesics in patients with cancer pain: An exploratory study. Issue 4 (14th September 2018)

6. Impact of coexisting gene mutations in EGFR-mutated non–small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs. (January 2020)

7. Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations. Issue 1 (December 2015)

8. Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer (WJOG10217L). Issue 1 (16th February 2020)

10. The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma. Issue 1 (December 2016)